TXMD - TherapeuticsMD jumps 15% after Q3 growth in net revenue prescriptions across product portfolio and tops revenue consensus

TherapeuticsMD ([[TXMD]] +14.8%) Q3 results:Revenue of $19.3M (-18.5% Y/Y) vs consensus of $15.44M; Annovera revenue of $6.4M (+250% Q/Q).Imvexxy revenue (+35 Q/Q) to $6.8M.BIJUVA revenue (+22 Q/Q) to $1.6M.Gross margin increased to 83%, compared to 59% for the quarter ended June 30, 2020.Net loss: ($32.6M); loss/share: ($0.12) (+7.7%) vs consensus of ($0.13); CF Ops: ($129.1M) (-12.4%).The Company entered into an agreement with its lender, Sixth Street Partners, to lower the minimum cash balance requirement under the Company’s Financing Agreement from $60M to $45M through year end.The company is in process to divest vitaCare Prescription Services underway that could generate non-dilutive proceeds.Previously: Therapeutics MD EPS beats by $0.01, beats on revenue (Nov.09).

For further details see:

TherapeuticsMD jumps 15% after Q3 growth in net revenue, prescriptions across product portfolio and tops revenue consensus